Researchers have identified new drug targets for therapies that could benefit patients with different forms of retinitis pigmentosa and other inherited retinal diseases. Using advanced proteomics ...

• Compared to human experts, artificial intelligence (AI)-based tests may be comparably accurate at detecting the exudative (or wet) form of age-related macular degeneration (eAMD). • There were no ...

An international team of researchers has identified new drug targets for therapies that could benefit patients with different ...

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet ...

The quest to find a cure for the UK’s biggest cause of sight loss will be brought sharply into focus at a support group for ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2025, according to Statista. A large portion of that figure is from the oncology segment, which is expected ...

Therefore, Belite Bio is evaluating safety and efficacy of Tinlarebant in GA patients in a 2-year Phase 3 study (PHOENIX). Belite Bio is a clinical-stage biopharmaceutical drug development company ...

Faricimab, a humanized, bispecific, immunoglobulin G monoclonal antibody, received FDA approval as an intravitreal injection ...

Improving global diversity of global datasets will enable researchers to better serve underrepresented groups and advance our ...

Retinal neuroprotection is a critical area of research focused on preventing or slowing the degeneration of retinal neurons, ...

Ocugen (NASDAQ:OCGN) said the FDA has removed a clinical hold on its Investigational New Drug application for a Phase 1 study ...